Kwality Pharmaceuticals Ltd

Kwality Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Kwality Pharmaceuticals Ltd

₹ 2,299 3.60%
02 Jun - close price
kwalitypharma.com BSE: 539997 NSE: KPL
About

Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products[1]

Key Points

Business Overview:[1][2]
KPL is in an ANVISA and EU GMP certified manufacturer of all pharma products including complex molecules across all dosage forms including niche Biologics. It has a portfolio of 3000+ formulations across 25+ therapeutic areas with categories including generics, cephalosporin, beta-lactam, oncology & biologics. It manufactures and deals in drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations

Website BSE NSE
  • Market Cap ₹ 2,385 Cr.
  • Current Price ₹ 2,299
  • High / Low ₹ 2,390 / 829
  • Stock P/E 35.1
  • Book Value ₹ 320
  • Dividend Yield 0.00 %
  • ROCE 24.2 %
  • ROE 22.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter
  • Company has delivered good profit growth of 35.0% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 18.2%
  • Company's median sales growth is 27.4% of last 10 years

Cons

  • Stock is trading at 7.19 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has high debtors of 203 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
69 67 70 78 92 80 90 84 116 111 111 123 157
57 54 54 61 71 63 70 67 90 87 86 93 118
Operating Profit 11 14 15 17 21 17 20 18 26 24 25 30 39
OPM % 17% 20% 22% 21% 22% 22% 22% 21% 22% 22% 23% 24% 25%
-15 0 0 1 -7 0 0 1 1 0 1 -0 1
Interest 2 2 2 3 3 2 3 2 2 3 3 2 3
Depreciation 4 5 5 5 5 4 5 5 5 5 5 5 5
Profit before tax -10 7 8 10 6 11 13 11 19 17 18 22 32
Tax % -24% 25% 24% 21% 29% 25% 33% 25% 24% 30% 23% 28% 20%
-7 5 6 8 4 8 8 9 14 12 14 16 25
EPS in Rs -7.11 5.22 6.01 7.41 4.20 8.06 8.16 8.22 13.96 11.50 13.61 15.43 24.38
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
52 74 98 137 166 139 262 456 251 307 370 503
49 69 89 126 150 125 233 285 190 241 290 385
Operating Profit 3 5 9 12 16 14 29 172 61 66 80 118
OPM % 6% 7% 9% 8% 9% 10% 11% 38% 24% 22% 22% 24%
0 0 1 1 1 4 2 4 -14 -5 2 2
Interest 1 1 2 2 2 3 3 3 7 10 10 11
Depreciation 1 2 3 3 3 4 6 11 15 20 18 20
Profit before tax 1 2 6 7 11 11 21 162 26 31 54 89
Tax % 41% 48% 42% 39% 31% 25% 30% 26% 25% 24% 26% 25%
1 1 3 4 8 8 15 120 19 24 40 67
EPS in Rs 0.92 1.55 3.23 4.39 7.28 8.02 14.60 115.64 18.67 22.94 38.41 64.91
Dividend Payout % 0% 0% 9% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 21%
5 Years: 14%
3 Years: 26%
TTM: 36%
Compounded Profit Growth
10 Years: 44%
5 Years: 35%
3 Years: 29%
TTM: 71%
Stock Price CAGR
10 Years: %
5 Years: 86%
3 Years: 99%
1 Year: 147%
Return on Equity
10 Years: 26%
5 Years: 27%
3 Years: 18%
Last Year: 23%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 4 5 5 10 10 10 10 10 10 10 10 10
Reserves 15 17 20 19 27 36 51 171 190 214 254 321
8 13 19 26 29 35 41 54 90 98 112 130
10 17 26 40 39 52 64 105 70 72 71 130
Total Liabilities 37 51 71 96 105 133 166 341 361 394 447 592
13 13 17 20 29 43 57 92 120 139 146 156
CWIP 0 0 0 0 0 0 3 12 14 0 0 17
Investments 1 2 4 5 5 4 5 0 0 0 0 0
24 37 50 70 71 86 102 237 226 255 302 420
Total Assets 37 51 71 96 105 133 166 341 361 394 447 592

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1 -3 4 -1 14 6 27 61 41 43 53 17
-1 -2 -7 -6 -12 -18 -23 -63 -48 -26 -29 -35
1 6 5 5 -2 12 1 6 1 -17 -14 7
Net Cash Flow 1 0 2 -1 -0 0 4 3 -6 -1 10 -11
Free Cash Flow -0 -5 -2 -7 2 -12 3 5 -4 17 28 -29
CFO/OP 51% -30% 76% 21% 108% 62% 115% 59% 78% 67% 85% 32%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 63 89 84 98 84 79 50 55 104 136 152 203
Inventory Days 61 67 71 54 34 94 38 97 310 187 167 111
Days Payable 40 63 65 80 52 96 58 63 117 106 112 144
Cash Conversion Cycle 85 93 90 73 67 77 30 90 297 217 208 170
Working Capital Days 35 41 20 18 20 43 24 60 118 101 98 128
ROCE % 9% 13% 19% 19% 22% 18% 26% 98% 19% 16% 18% 24%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Manufacturing Units
Units

Log in to view insights

Please log in to see hidden values.

Login
Export Presence (Number of Countries)
Countries
Number of Products / Formulations
SKUs
Number of Product Registrations
Units
Team Strength (Employees)
Employees

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
54.73% 54.76% 54.76% 54.82% 54.82% 54.82% 54.82% 54.82% 54.82% 54.82% 54.82% 54.87%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.50% 2.79%
0.01% 0.01% 0.01% 0.00% 0.00% 0.02% 0.03% 0.32% 0.33% 0.33% 0.33% 0.36%
45.25% 45.22% 45.22% 45.17% 45.18% 45.15% 45.14% 44.86% 44.86% 44.83% 44.33% 41.99%
No. of Shareholders 6,9436,2915,7865,6955,2737,4878,9479,42010,11511,59510,70910,555

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls

  • May 2026
    Transcript PPT
  • Feb 2026
    Transcript
    PPT REC
  • Jun 2025
    Transcript
    AI Summary
    PPT
  • May 2024
    Transcript
    AI Summary
    PPT
  • May 2024
    Transcript
    AI Summary
    PPT
  • Aug 2023
    Transcript
    AI Summary
    PPT
  • May 2022
    Transcript
    AI Summary
    PPT